The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit Wednesday, but rising competition ...

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

The drugmaker is a large and consistent client for Covington. The law firm has represented Novo Nordisk in several dozen ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

Levi & Korsinsky is representing the shareholder plaintiff in a suit claiming the Ozempic and Wegovy manufacturer withheld ...

Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.